Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Holding PEN?
Track your performance easily
PEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$148.00 - $277.89
Previous CloseN/A
Volume93.15K
Average Volume (3M)439.90K
Market Cap
$10.52B
Enterprise Value$7.55B
Total Cash (Recent Filing)$128.75M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)318.3
Beta0.90
Next Earnings
Feb 25, 2025EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding38,379,200
10 Day Avg. Volume510,689
30 Day Avg. Volume439,900
Standard Deviation0.14
R-Squared0.04
Alpha0.00949
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.04
Price to Cash Flow (P/CF)46.60
P/FCF Ratio51.50
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue6.49
Enterprise Value/Gross Profit11.06
Enterprise Value/Ebitda-2.23K
Forecast
1Y Price Target
$266.21Price Target Upside-1.70% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Penumbra News
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesPenetration of MT into PEN's DVT and PE markets is low, representing a significant growth opportunity as clinical trials drive awareness of MT benefits.
Market LeadershipPEN is a leader in the mechanical thrombectomy (MT) market with a broad product portfolio across a number of segments including deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and arterial, among others.
Product InnovationPEN's new Lightning Flash computer-assisted vacuum thrombectomy platform positions the company to capture meaningful market share through increased efficiencies.
Bears Say
Product InterestInterest is waning for super bore aspiration catheters, contrary to some recent checks.
Revenue GuidanceCaution is advised regarding 2025 revenue guidance as there is a belief that current expectations might be too optimistic.
Study DelaysThe study has taken longer than expected after the FDA requested a change to the safety endpoint and increased enrollment.
---
Ownership Overview
3.44% Insiders
41.41% Mutual Funds
― Other Institutional Investors
33.32% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $277.89 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $10.52B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is Feb 25, 2025 which is in 26 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Oct 30, 2024. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.687 by $0.163.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Overvalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 0.9.
How many shares outstanding does Penumbra have?
Penumbra has 38,379,200 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.85 in its last earnings report, beating expectations of $0.687. Following the earnings report the stock price went up 8.32%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in PEN
---
Penumbra Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.21 (-1.70% Downside)
$266.21 (-1.70% Downside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 27.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.09%
12-Months-Change
Fundamentals
Return on Equity
3.13%
Trailing 12-Months
Asset Growth
0.73%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance in the U.S. market, particularly in the thrombectomy business, and improving profitability metrics. However, international challenges, particularly in China and the European reimbursement landscape, tempered the overall outlook.Read More>---
PEN Stock 12 Month Forecast
Average Price Target
$266.21
▼(-1.70% Downside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Best Analysts Covering PEN
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+5.18%
reiterated a buy rating last month
Copying Richard Newitter's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +5.18% per trade.
---